LEADER 01776nam  2200421Ia 450 
001 9910696615703321
005 20080619115056.0
035   $a(CKB)5470000002380708
035   $a(OCoLC)232330615
035   $a(EXLCZ)995470000002380708
100   $a20080619d2008      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug safety$b[electronic resource] $epreliminary findings suggest recent FDA initiatives have potential, but do not fully address weaknesses in its foreign drug inspection program : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives /$fstatement of Marcia Crosse
210  1$a[Washington, D.C.] :$cU.S. Govt. Accountability Office,$d[2008]
215   $a19 pages $cdigital, PDF file
225 1 $aTestimony ;$vGAO-08-701 T
300   $aTitle from title screen (viewed on May 29, 2008).
300   $a"For release ... April 22, 2008."
300   $aPaper version available from: U.S. Govt. Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aDrug safety 
606   $aDrugs$xSafety measures
606   $aDrugs$xInspection
615  0$aDrugs$xSafety measures.
615  0$aDrugs$xInspection.
700   $aCrosse$b Marcia$01380679
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Energy and Commerce.$bSubcommittee on Oversight and Investigations.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696615703321
996   $aDrug safety$93449630
997   $aUNINA